IDH mutations are observed in approximately 80% of WHO grade II and III gliomas, and LGG with such mutations is more likely to develop into secondary GBM.[28,29] In this study, the IDH1 mutation rates were as high as 90% and 67% in the LR and HR teams, respectively. Here, IDH2 is linked to central nervous system cancer.